Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for XOMA Royalty Corporation (XOMA : NSDQ)

• Company Description    XOMA ROYALTY is a biotechnology royalty aggregator. The company acquires the potential future economics associated with pre-commercial therapeutic candidates which have been licensed to pharmaceutical or biotechnology companies. XOMA ROYALTY, formerly known as XOMA Corporation, is based in EMERYVILLE, Calif. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $37.72 Daily Weekly Monthly 20 Day Moving Average: 56,364 shares Shares Outstanding: 12.09 (millions) Market Capitalization: $455.95 (millions) Beta: 0.99 52 Week High: $38.00 52 Week Low: $18.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 19.41% 17.25% 12 Week 53.21% 39.10% Year To Date 43.53% 28.15%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2200 POWELL STREET SUITE 310 - EMERYVILLE,CA 94608 USA ph: 510-204-7200 fax: 510-649-7571 investorrelations@xoma.com http://www.xoma.com

• General Corporate Information    Officers Owen Hughes - Chief Executive Officer and Director Jack L. Wyszomierski - Chairman of the Board Thomas Burns - Senior Vice President; Finance and Chief Financial Heather L. Franklin - Director Natasha Hernday - Director Peer Information XOMA Royalty Corporation (CORR.) XOMA Royalty Corporation (RSPI) XOMA Royalty Corporation (CGXP) XOMA Royalty Corporation (BGEN) XOMA Royalty Corporation (GTBP) XOMA Royalty Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98419J206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 12.09 Most Recent Split Date: 10.00 (0.05:1) Beta: 0.99 Market Capitalization: $455.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.88 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: 42.86 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.24 Price/Cash Flow: - Price / Sales: 10.15 EPS Growth vs. Year Ago Period: 271.43% vs. Previous Quarter: 700.00% Sales Growth vs. Year Ago Period: 18.43% vs. Previous Quarter: -17.49% ROE 06/30/25 - 2.63 03/31/25 - -12.43 12/31/24 - -25.08 ROA 06/30/25 - 0.97 03/31/25 - -4.85 12/31/24 - -9.64 Current Ratio 06/30/25 - 4.88 03/31/25 - 5.54 12/31/24 - 5.15 Quick Ratio 06/30/25 - 4.88 03/31/25 - 5.54 12/31/24 - 5.15 Operating Margin 06/30/25 - 4.74 03/31/25 - -25.44 12/31/24 - -76.82 Net Margin 06/30/25 - -27.57 03/31/25 - -13.04 12/31/24 - -58.15 Pre-Tax Margin 06/30/25 - -34.07 03/31/25 - -19.85 12/31/24 - -68.38 Book Value 06/30/25 - 6.05 03/31/25 - 7.08 12/31/24 - 6.95 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 1.41 03/31/25 - 1.18 12/31/24 - 1.31 Debt-to-Capital 06/30/25 - 62.79 03/31/25 - 54.15 12/31/24 - 56.61

Powered by Zacks Investment Research ©